Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Plos One
|
July 5, 2024
Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer
Emily Tsutsumi, Anne M Macy, Janine LoBello, et al.
Current Opinion in Immunology
|
May 2, 2023
Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells
Anne M Macy, Lauren M Herrmann, Anngela C Adams, et al.
The Journal of Investigative Dermatology
|
July 12, 2021
Solar Simulated Light Induces Cutaneous Squamous Cell Carcinoma in Inbred Mice: A Clinically Relevant Model to Investigate T-Cell Responses
Anngela C Adams, Anne M Macy, Kathylynn Saboda, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 29, 2026
MHC class II on melanoma cells regulates the anti-tumor T cell response
Anne M Macy, Lauren M Herrmann, Erin M Thornley, et al.
Cell Communication and Signaling : CCS
|
February 12, 2026
Interferon-gamma-inducible protein 30 prevents IFN-γ-receptor 1 degradation to maintain PD-L1 and MHC-II levels in metastatic melanoma
Shodai Mizuno, Yuka Mizuno, Kodai Abe, et al.
Cancers
|
May 14, 2022
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
Anngela C Adams, Elizabeth S Borden, Anne M Macy, et al.
Translational Oncology
|
May 22, 2022
Corrigendum to "Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest"
Anngela C Adams, Anne M Macy, Paul Kang, et al.
Translational Oncology
|
November 4, 2021
Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest
Anngela C Adams, Anne M Macy, Paul Kang, et al.
Biorxiv : the Preprint Server for Biology
|
February 26, 2024
Distinct sets of molecular characteristics define tumor-rejecting neoantigens
Anngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Journal for Immunotherapy of Cancer
|
October 22, 2025
Structural changes from wild-type define tumor-rejecting neoantigens
Anngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Plos One
|
July 5, 2024
Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer
Emily Tsutsumi, Anne M Macy, Janine LoBello, et al.
Current Opinion in Immunology
|
May 2, 2023
Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells
Anne M Macy, Lauren M Herrmann, Anngela C Adams, et al.
The Journal of Investigative Dermatology
|
July 12, 2021
Solar Simulated Light Induces Cutaneous Squamous Cell Carcinoma in Inbred Mice: A Clinically Relevant Model to Investigate T-Cell Responses
Anngela C Adams, Anne M Macy, Kathylynn Saboda, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 29, 2026
MHC class II on melanoma cells regulates the anti-tumor T cell response
Anne M Macy, Lauren M Herrmann, Erin M Thornley, et al.
Cell Communication and Signaling : CCS
|
February 12, 2026
Interferon-gamma-inducible protein 30 prevents IFN-γ-receptor 1 degradation to maintain PD-L1 and MHC-II levels in metastatic melanoma
Shodai Mizuno, Yuka Mizuno, Kodai Abe, et al.
Cancers
|
May 14, 2022
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
Anngela C Adams, Elizabeth S Borden, Anne M Macy, et al.
Translational Oncology
|
May 22, 2022
Corrigendum to "Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest"
Anngela C Adams, Anne M Macy, Paul Kang, et al.
Translational Oncology
|
November 4, 2021
Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest
Anngela C Adams, Anne M Macy, Paul Kang, et al.
Biorxiv : the Preprint Server for Biology
|
February 26, 2024
Distinct sets of molecular characteristics define tumor-rejecting neoantigens
Anngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Journal for Immunotherapy of Cancer
|
October 22, 2025
Structural changes from wild-type define tumor-rejecting neoantigens
Anngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Page
of 2